巨噬细胞与冠心病的相关性研究进展

doi:10.3969/j.issn.1003-9198.2021.12.003

摘要/Abstract

中图分类号:

R 541.4

罗彬, 崔檬, 王佳贺. 巨噬细胞与冠心病的相关性研究进展[J]. 实用老年医学, 2021, 35(12): 1222-1224.

[1] 《中国心血管健康与疾病报告2020》编写组.《中国心血管健康与疾病报告2020》概述[J]. 中国心血管病研究,2021,19(7):582-590.
[2] HE X, MATAM B R, BELLARY S, et al. CHD risk minimization through lifestyle control: machine learning gateway [J]. Sci Rep, 2020, 10(1): 4090.
[3] PARK I, KASSITERIDI C, MONACO C. Functional diversity of macrophages in vascular biology and disease [J]. Vascul Pharmacol, 2017, 99: 13-22.
[4] XU H, JIANG J, CHEN W, et al. Vascular macrophages in atherosclerosis [J]. J Immunol Res, 2019, 2019: 4354786.
[5] MOORE K J, SHEEDY F J, FISHER E A. Macrophages in atherosclerosis: a dynamic balance [J]. Nat Rev Immunol, 2013, 13(10): 709-721.
[6] GROH L, KEATING S T, JOOSTEN L A B, et al. Monocyte and macrophage immunometabolism in atherosclerosis [J]. Semin Immunopathol, 2018, 40(2): 203-214.
[7] BORING L, GOSLING J, CLEARY M, et al. Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis [J]. Nature, 1998, 394(6696): 894-897.
[8] YANG S, YUAN H Q, HAO Y M, et al. Macrophage polarization in atherosclerosis [J]. Clin Chim Acta, 2020, 501: 142-146.
[9] MESTAS J, LEY K. Monocyte-endothelial cell interactions in the development of atherosclerosis [J]. Trends Cardiovasc Med, 2008, 18(6): 228-232.
[10] LUO W, WANG H, OHMAN M K, et al. P-selectin glycoprotein ligand-1 deficiency leads to cytokine resistance and protection against atherosclerosis in apolipoprotein E deficient mice [J]. Atherosclerosis, 2012, 220(1): 110-117.
[11] SWIRSKI F K, NAHRENDORF M, ETZRODT M, et al. Identification of splenic reservoir monocytes and their deployment to inflammatory sites [J]. Science, 2009, 325(5940): 612-616.
[12] ADAMSON S, LEITINGER N. Phenotypic modulation of macrophages in response to plaque lipids [J]. Curr Opin Lipidol, 2011, 22(5): 335-342.
[13] MANTOVANI A, SICA A, SOZZANI S, et al. The chemokine system in diverse forms of macrophage activation and polarization [J]. Trends Immunol, 2004, 25(12): 677-686.
[14] CHINETTI-GBAGUIDI G, COLIN S, STAELS B. Macrophage subsets in atherosclerosis [J]. Nat Rev Cardiol, 2015, 12(1): 10-17.
[15] AMENGUAL J, BARRETT T J. Monocytes and macrophages in atherogenesis [J]. Curr Opin Lipidol, 2019, 30(5): 401-408.
[16] BOYLE J J, HARRINGTON H A, PIPER E, et al. Coronary intraplaque hemorrhage evokes a novel atheroprotective macrophage phenotype [J]. Am J Pathol, 2009, 174(3): 1097-1108.
[17] TABAS I. Macrophage death and defective inflammation resolution in atherosclerosis [J]. Nat Rev Immunol, 2010, 10(1): 36-46.
[18] FEIG J E, VENGRENYUK Y, REISER V, et al. Regression of atherosclerosis is characterized by broad changes in the plaque macrophage transcriptome [J]. PLoS One, 2012, 7(6): e39790.
[19] RAHMAN K, VENGRENYUK Y, RAMSEY S A, et al. Inflammatory Ly6Chi monocytes and their conversion to M2 macrophages drive atherosclerosis regression [J]. J Clin Invest, 2017, 127(8): 2904-2915.
[20] LI J, LEI H T, CAO L, et al. Crocin alleviates coronary atherosclerosis via inhibiting lipid synthesis and inducing M2 macrophage polarization [J]. Int Immunopharmacol, 2018, 55: 120-127.
[21] MOMTAZI-BOROJENI A A, ABDOLLAHI E, NIKFAR B, et al. Curcumin as a potential modulator of M1 and M2 macrophages: new insights in atherosclerosis therapy [J]. Heart Fail Rev, 2019, 24(3): 399-409.
[22] ZHANG X, LIU M H, QIAO L, et al. Ginsenoside Rb1 enhances atherosclerotic plaque stability by skewing macrophages to the M2 phenotype [J]. J Cell Mol Med, 2018, 22(1): 409-416.
[23] BRENNER C, FRANZ W M, KüHLENTHAL S, et al. DPP-4 inhibition ameliorates atherosclerosis by priming monocytes into M2 macrophages [J]. Int J Cardiol, 2015, 199: 163-169.
[24] BRUEN R, CURLEY S, KAJANI S, et al. Liraglutide dictates macrophage phenotype in apolipoprotein E null mice during early atherosclerosis [J]. Cardiovasc Diabetol, 2017, 16(1): 143.
[25] HAVERSLAG R, PASTERKAMP G, HOEFER I E. Targeting adhesion molecules in cardiovascular disorders [J]. Cardiovasc Hematol Disord Drug Targets, 2008, 8(4): 252-260.
[26] TIWARI R L, SINGH V, BARTHWAL M K. Macrophages: an elusive yet emerging therapeutic target of atherosclerosis [J]. Med Res Rev, 2008, 28(4): 483-544.
[27] WANG Y, WANG G Z, RABINOVITCH P S, et al. Macrophage mitochondrial oxidative stress promotes atherosclerosis and nuclear factor-κB-mediated inflammation in macrophages [J]. Circ Res, 2014, 114(3): 421-433.

巨噬细胞与冠心病的相关性研究进展

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

Metrics

推荐阅读 10

[1]	顾崇怀, 项学军, 郑元喜, 乔锐, 林松. 达格列净对接受冠状动脉介入治疗的伴有射血分数降低的心力衰竭合并2型糖尿病老年病人疗效观察[J]. 实用老年医学, 2024, 38(10): 1025-1029.
[2]	徐寿勇, 袁勇. 老年病人开展双低剂量CT冠状动脉造影的可行性研究[J]. 实用老年医学, 2024, 38(10): 1054-1058.
[3]	查志敏, 刘欢, 王向明, 李秋爽, 郭妍. 心脏瓣膜钙化对老年冠心病病人预后的影响[J]. 实用老年医学, 2024, 38(3): 245-250.
[4]	朱晨晨, 秦海东. 斑块侵蚀在急慢性冠脉综合征发生发展中的作用[J]. 实用老年医学, 2024, 38(3): 308-311.
[5]	章颖, 谢玲, 叶佳琦, 羌文慧, 严晓云, 姜英, 张清. 层粘连蛋白与老年急性心肌梗死病人主要不良心血管事件的相关性[J]. 实用老年医学, 2024, 38(2): 149-151.
[6]	杨雪, 甯春, 赵娟, 郝敬波, 杨荣礼. 生长分化因子15和细胞因子对老年冠心病合并衰弱病人的诊断价值[J]. 实用老年医学, 2023, 37(10): 1009-1013.
[7]	郑亚国, 许田, 左广锋, 陈亮, 林松. 药物涂层球囊治疗老年冠状动脉分支开口病变病人的疗效观察[J]. 实用老年医学, 2023, 37(6): 599-602.
[8]	宋春梅, 尹亚娟, 刘永升, 郭岐峰, 陈洁, 魏梅. 焦虑对老年经皮冠状动脉介入治疗术后病人不良心血管事件的预测价值[J]. 实用老年医学, 2023, 37(4): 352-355.
[9]	黄多新, 周杰, 严凌, 李必龙, 叶露, 林松, 赵莹莹. 衰弱对老年冠心病病人心功能及PCI术并发症的影响[J]. 实用老年医学, 2023, 37(4): 395-397.
[10]	姜磊, 贾志强, 俞建, 李晓庆, 张冬梅, 黄菁菁. 强化瑞舒伐他汀治疗对老年急性冠脉综合征病人PCI术后炎性衰老相关指标的影响及临床疗效[J]. 实用老年医学, 2023, 37(3): 265-269.
[11]	王思佳, 韩旭. 老年稳定性冠心病合并颈动脉斑块中医药治疗研究进展[J]. 实用老年医学, 2023, 37(2): 109-111.
[12]	嵇佳林, 刘晶, 王雪黎, 冯泓琳, 韩旭. 冠心平片治疗冠心病的Meta分析和序贯分析[J]. 实用老年医学, 2023, 37(2): 128-133.
[13]	魏梅, 郭岐峰, 段立楠, 尹亚娟, 刘刚, 郑明奇, 刘永升. 亚临床甲状腺功能减退与老年病人经皮冠状动脉介入治疗术后死亡的相关性研究[J]. 实用老年医学, 2023, 37(2): 138-141.
[14]	姚俊秀, 郭进春, 郝小丹, 李龙心, 杨雪, 王璋. 慢性冠状动脉综合征病人肝细胞生长因子的表达及其诊断价值[J]. 实用老年医学, 2023, 37(2): 173-177.
[15]	张越, 李晓庆, 鲁翔. 脂蛋白相关磷脂酶A2在冠心病诊治方面的研究进展[J]. 实用老年医学, 2023, 37(2): 191-194.